Impedimed (ASX:IPD) share price rises with 46% lift in revenues

Let's take a closer look.

| More on:
heavy lifting, lifting index, carrying weight, boy lifting dumbbell above his head

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Impedimed Limited (ASX: IPD) share price is appreciating after the company released its full-year results for FY21.

At the time of writing, shares in the healthcare company are trading for 13 cents each – up 4%. For context, the ASX All Ordinaries Index (ASX: XAO) is 0.25% higher.

Let's take a closer look at today's announcement.

Impedimed share price lifts with reduction in losses

  • Revenue of $8.4 million – up 46.5% on the prior corresponding period (pcp). This includes a 64% growth in revenue from its SOZO software, which totalled $7.6 million.
  • Loss from ordinary activities of $20.7 million, which is down 3% on the pcp.
  • Net operating cash outflows for the period of $13.3 million. This is down from the $19.2 million outflow in the pcp.
  • Nil dividend paid for the year, which is the same as FY20.

What happened in FY21 for Impedimed?

The Impedimed share price rocketed 13% in November when AstraZeneca plc (LSE: AZN) announced it was using SOZO for phase II clinical trials. The product was used for measuring fluid volumes in patients with chronic kidney disease.

Besides SOZO, Impedimed also announced news in relation to its 'Prevent' treatment and 'HF-Dex' system.

What did management say?

Impedimed CEO and Managing Director, Richard Carreon, said

Our transition to a connected digital health platform put the Company in a strong position to thrive during a very turbulent year. We have built a strong and resilient business, with quarter-over-quarter record results. Throughout the past year, our Company continued to prove its resilience, as we signed SOZO contracts in excess of $12.0 million, had a churn rate of just 1%, and a contract renewal rate of 100% throughout the entire financial year.

What's next for Impedimed?

Just in the last 2 days, Impedimed released 2 statements that were material to the Impedimed share price.

The first relates to designation of a product in the US and the second on an R&D tax rebate.

On the first matter, SOZO received "Breakthrough Device Designation" from the US Food and Drug Administration (FDA) for use in renal patients. The product will be used to measure fluids in patients undergoing dialysis. The company says the designation is the "perfect forum" to ultimately get FDA clearance.

On the second, the company received a $1.8 million research and development (R&D) from the Australian government. Last year the company received a $2.6 million refund.

Impedimed share price snapshot

Over the past 12 months, the Impedimed share price has increased 62.5%. Year-to-date, however, it is only up 8.33%. This is below the All Ords Index. Impedimed has a market capitalisation of about $187 million.

Motley Fool contributor Marc Sidarous has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

a man in a business suit sits at his laptop computer at his desk and smiles broadly in an office setting, giving an air of optimism and confidence.
Share Gainers

Why these three ASX All Ords stocks are leading the charge higher this week

These three ASX All Ords shares rocketed higher this week. But how?

Read more »

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Botanix, Strike Energy, Talga, and West African Resources shares are pushing higher

These shares are ending the week on a high. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

If you invested $5,000 in this ASX healthcare stock a year ago, you'd have $50,833 now!

The little-known ASX healthcare stock has delivered eye-watering 12-month gains. But how?

Read more »

A young bearded man wearing a white t-shirt with a yellow backdrop holds up his arms to his chest and points to the camera in celebration of ASX shares rising today
Share Gainers

Why Bigtincan, DroneShield, Guzman Y Gomez, and Helia shares are racing higher

These shares are having strong sessions on Thursday. But why?

Read more »

Three girls compete in a race, running fast around an athletic track.
Share Gainers

Here's why ASX uranium shares like Deep Yellow are running hot today

ASX uranium stocks are on fire this Wednesday.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Chrysos, Hansen Technologies, Pantoro, and WA1 Resources shares are pushing higher

These shares are having a good time on hump day. But why?

Read more »

piggy bank at end of winding road
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors enjoyed a lucrative Tuesday session today.

Read more »

A man sees some good news on his phone and gives a little cheer.
Share Gainers

Why Capitol Health, Infratil, Newmont, and Race Oncology shares are charging higher

These shares are having a good session. But why?

Read more »